Immunomodulatory therapy for chronic hepatitis B virus infection

Fundamental and Clinical Pharmacology

Volumn 19, Issue 1, 2005, Pages 17-26

  Sprengers, D ^a   Janssen, H L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti viral therapy; Chronic hepatitis B; Immune response; Immunomodulatory therapy

Indexed keywords

ALPHA TOCOPHEROL; DNA VACCINE; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; NUCLEOSIDE ANALOG; RECOMBINANT HEPATITIS B VACCINE; THYMOSIN ALPHA1;

CHRONIC HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION CONTROL; LIVER CELL; LIVER CELL CARCINOMA; LIVER FAILURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; T LYMPHOCYTE; VIRUS MUTANT;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; CYTOKINES; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; THYMOSIN; VITAMIN E;

EID: 13444282203     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2004.00300.x     Document Type: Review

References (79)

1. Kane M. Global programme for control of hepatitis B infection. Vaccine (1995) 13(Suppl. 1) S47-S49.
2. Wright T.L., Lau J.Y. Clinical aspects of hepatitis B virus infection. Lancet (1993) 342 1340-1344.
3. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. (1995) 13 29-60.
4. Benhamou Y., Dohin E., Lunel-Fabiani F. et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet (1995) 345 396-397.
5. Lai C.L., Chien R.N., Leung N.W. et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. (1998) 339 61-68.
6. Angus P., Vaughan R., Xiong S. et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 125 292-297.
7. Maini M.K., Boni C., Lee C.K. et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. (2000) 191 1269-1280.
8. Rehermann B., Lau D., Hoofnagle J.H., Chisari F.V. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J. Clin. Invest. (1996) 97 1655-1665.
9. Livingston B.D., Crimi C., Grey H. et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. (1997) 159 1383-1392.
10. Guidotti L.G., Ando K., Hobbs M.V. et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl Acad. Sci. USA (1994) 91 3764-3768.
11. Rehermann B. Intrahepatic T cells in hepatitis B: viral control versus liver cell injury. J. Exp. Med. (2000) 191 1263-1268.
12. Ganem D. Persistent infection of humans with hepatitis B virus: mechanisms and consequences. Rev. Infect. Dis. (1982) 4 1026-1047.
13. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science (1999) 284 825-829.
14. Heise T., Guidotti L.G., Cavanaugh V.J., Chisari F.V. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J. Virol. (1999) 73 474-481.
15. Guidotti L.G., Chisari F.V. Cytokine-mediated control of viral infections. Virology (2000) 273 221-227.
16. Barnaba V., Franco A., Alberti A., Balsano C., Benvenuto R., Balsano F. Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection. J. Immunol. (1989) 143 2650-2655.
17. Ferrari C., Penna A., Giuberti T. et al. Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. J. Immunol. (1987) 139 2050-2058.
18. Lok A.S., Heathcote E.J., Hoofnagle J.H. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology (2001) 120 1828-1853.
19. Hadziyannis S.J., Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2001) 34 617-624.
20. Oritani K., Kincade P.W., Zhang C., Tomiyama Y., Matsuzawa Y. Type I interferons and limitin: a comparison of structures, receptors, and functions. Cytokine Growth Factor Rev. (2001) 12 337-348.
21. Levy D.E. Whence interferon? Variety in the production of interferon in response to viral infection. J. Exp. Med. (2002) 195 F15-F18.
22. Lau J.Y., Bain V.G., Naoumov N.V., Smith H.M., Alexander G.J., Williams R. Effect of interferon-gamma on hepatitis B viral antigen expression in primary hepatocyte culture. Hepatology (1991) 14 975-979.
23. Niederau C., Heintges T., Lange S. et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. (1996) 334 1422-1427.
24. Villeneuve J.P., Condreay L.D., Willems B. et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology (2000) 31 207-210.
25. van Zonneveld M., Honkoop P., Hansen B.E. et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology (2004) 39 804-810.
26. Wong D.K., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. (1993) 119 312-323.
27. Schalm S.W., Heathcote J., Cianciara J. et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut (2000) 46 562-568.
28. Janssen H.L., Gerken G., Carreno V. et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology (1999) 30 238-243.
29. Lampertico P., Del Ninno E., Vigano M. et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology (2003) 37 756-763.
30. Lok A.S., Chung H.T., Liu V.W., Ma O.C. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology (1993) 105 1833-1838.
31. Lin S.M., Sheen I.S., Chien R.N., Chu C.M., Liaw Y.F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology (1999) 29 971-975.
32. Ikeda K., Saitoh S., Suzuki Y. et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer (1998) 82 827-835.
33. Manesis E.K., Hadziyannis S.J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology (2001) 121 101-109.
34. Oliveri F., Santantonio T., Bellati G. et al. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am. J. Gastroenterol. (1999) 94 1366-1372.
35. Kozlowski A., Harris J.M. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Control Release (2001) 72 217-224.
36. Cooksley W.G., Piratvisuth T., Lee S.D. et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepat. (2003) 10 298-305.
37. Janssen H.L.A., Senturk H., Zeuzem S. et al. Peginterferon alfa-2B and lamivudine combination therapy compared with peginterferon alfa-2B for chronic HBeAg positive hepatitis B: a randomized controlled trial in 307 patients. Hepatology (2003) 38 1323.
38. Marcellin P., Lau G.K.K., Bonino F. et al. Peginterferon alfa-2a (40 KD) (pegasys) monotherapy is more effective than lamivudine monotherapy in the treatment of HBeAg-negative chronic hepatitis B: 73-week results from a phase III, partially double-blind study of pegasys alone vs. pegasys plus lamivudine vs. lamivudine. J. Hepatol. (2004) 40(Suppl. 1) 95A.
39. Onji M., Kondoh H., Horiike N. et al. Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis. Gut (1987) 28 1648-1652.
40. Gianotti N., Uberti-Foppa C., Boeri E. et al. Hepatitis B surface antigen clearance and appearance of antibodies against hepatitis B surface antigen after treatment with recombinant interleukin 2 in a human immunodeficiency virus-infected patient. Hepatology (2000) 32 1409-1410.
41. Tilg H., Vogel W., Tratkiewicz J. et al. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects. J. Hepatol. (1993) 19 259-267.
42. Thibault V., Delaugerre C., Calvez V., Costagliola D., Tubiana R., Katlama C. Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial. Hepatology (2002) 35 238-239.
43. Artillo S., Pastore G., Alberti A. et al. Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B. J. Med. Virol. (1998) 54 167-172.
44. Bruch H.R., Korn A., Klein H. et al. Treatment of chronic hepatitis B with interferon alpha-2b and interleukin-2. J. Hepatol. (1993) 17(Suppl. 3) S52-S55.
45. Dahmen A., Herzog-Hauff S., Bocher W.O., Galle P.R., Lohr H.F. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J. Med. Virol. (2002) 66 452-460.
46. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. (2003) 3 133-146.
47. Rossol S., Marinos G., Carucci P., Singer M.V., Williams R., Naoumov N.V. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J. Clin. Invest. (1997) 99 3025-3033.
48. Zeuzem S., Hopf U., Carreno V. et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology (1999) 29 1280-1287.
49. Markowicz S., Engleman E.G. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J. Clin. Invest. (1990) 85 955-961.
50. Fischer H.G., Frosch S., Reske K., Reske-Kunz A.B. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J. Immunol. (1988) 141 3882-3888.
51. Morrissey P.J., Bressler L., Park L.S., Alpert A., Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J. Immunol. (1987) 139 1113-1119.
52. Germain R.N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell (1994) 76 287-299.
53. Liehl E., Hildebrandt J., Lam C., Mayer P. Prediction of the role of granulocyte-macrophage colony-stimulating factor in animals and man from in vitro results. Eur. J. Clin. Microbiol. Infect. Dis. (1994) 13(Suppl. 2) S9-S17.
54. Martin J., Quiroga J.A., Bosch O., Carreno V. Changes in cytokine production during therapy with granulocyte-macrophage colony-stimulating factor in patients with chronic hepatitis B. Hepatology (1994) 20 1156-1161.
55. Van Thiel D.H., Friedlander L., Kania R.J., Molloy P.J., Hassanein T., Faruki H. A preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy. J. Viral Hepat. (1997) 4(Suppl. 1) 101-106.
56. Wen Y.M., Wu X.H., Hu D.C., Zhang Q.P., Guo S.Q. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet (1995) 345 1575-1576.
57. Pol S., Couillin I., Michel M.L. et al. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Acta Gastroenterol. Belg. (1998) 61 228-233.
58. Pol S., Nalpas B., Driss F. et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J. Hepatol. (2001) 34 917-921.
59. Jung M.C., Gruner N., Zachoval R. et al. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine (2002) 20 3598-3612.
60. Vitiello A., Ishioka G., Grey H.M. et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. (1995) 95 341-349.
61. Heathcote J., McHutchison J., Lee S. et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology (1999) 30 531-536.
62. Thermet A., Rollier C., Zoulim F., Trepo C., Cova L. Progress in DNA vaccine for prophylaxis and therapy of hepatitis B. Vaccine (2003) 21 659-662.
63. Davis H.L., McCluskie M.J., Gerin J.L., Purcell R.H. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl Acad. Sci. USA (1996) 93 7213-7218.
64. Roy M.J., Wu M.S., Barr L.J. et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine (2000) 19 764-778.
65. Li C.L., Zhang T., Saibara T. et al. Thymosin alpha1 accelerates restoration of T cell-mediated neutralizing antibody response in immunocompromised hosts. Int. Immunopharmacol. (2002) 2 39-46.
66. Sherman K.E., Jones C.C., Goldstein A.L., Naylor P.H. Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus. Viral Immunol. (1991) 4 195-199.
67. Chien R.N., Liaw Y.F., Chen T.C., Yeh C.T., Sheen I.S. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology (1998) 27 1383-1387.
68. Andreone P., Cursaro C., Gramenzi A. et al. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody - and hepatitis B virus DNA - positive chronic hepatitis B. Hepatology (1996) 24 774-777.
69. Chan H.L., Tang J.L., Tam W., Sung J.J. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol. Ther. (2001) 15 1899-1905.
70. Mutchnick M.G., Lindsay K.L., Schiff E.R. et al. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J. Viral Hepat. (1999) 6 397-403.
71. Zavaglia C., Severini R., Tinelli C. et al. A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe. HBV-DNA-positive chronic hepatitis B. Dig. Dis. Sci. (2000) 45 690-696.
72. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity (1996) 4 25-36.
73. Sugahara S., Ichida T., Yamagiwa S. et al. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatol. Res. (2002) 24 346-354.
74. Lau G.K., Nanji A., Hou J. et al. Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. J. Viral Hepat. (2002) 9 280-287.
75. Meydani M. Vitamin E. Lancet (1995) 345 170-175.
76. Gogu S.R., Blumberg J.B. Vitamin E increases interleukin-2 dependent cellular growth and glycoprotein glycosylation in murine cytotoxic T-cell line. Biochem. Biophys. Res. Commun. (1993) 193 872-877.
77. von Herbay A., Stahl W., Niederau C., Sies H. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free Radic. Res. (1997) 27 599-605.
78. Ota Y., Sasagawa T., Suzuki K. et al. Vitamin E supplementation increases polyunsaturated fatty acids of RBC membrane in HCV-infected patients. Nutrition (2004) 20 358-363.
79. Andreone P., Fiorino S., Cursaro C. et al. Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial. Antiviral Res. (2001) 49 75-81.